Azathioprine: Old drug, new actions

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1122-1124

  Maltzman, Jonathan S ^a,b   Koretzky, Gary A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOURIC ACID; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROTEIN BCL X; PURINE DERIVATIVE; RAC1 PROTEIN; RAPAMYCIN; TACROLIMUS; TIOGUANINE;

ACUTE LEUKEMIA; APOPTOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENTERITIS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY ALLOGRAFT REJECTION; NONHUMAN; NOTE; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD28; AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0037397004     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318384     Document Type: Note

References (20)

1. Elion, G.B. 1993. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann. N. Y. Acad. Sci. 685:400-407.
2. Murray, J.E., Merrill, J.P., Harrison, J.H., Wilson, R.E., and Dammin, G.J. 1963. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N. Engl. J. Med. 268:1315-1323.
3. Aarbakke, J., Janka-Schaub, G., and Elion, G.B. 1997. Thiopurine biology and pharmacology. Trends Pharmacol. Sci. 18:3-7.
4. Bretscher, P., and Cohn, M. 1970. A theory of self-nonself discrimination. Science. 169:1042-1049.
5. Lafferty, K.J., and Cunningham, A.J. 1975. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53:27-42.
6. Baxter, A.G., and Hodgkin, P.D. 2002. Activation rules: the two-signal theories of immune activation. Nat. Rev. Immunol. 2:439-446.
7. Schwartz, R.H. 2003. T Cell anergy. Annu. Rev. Immunol. 21:305-334.
8. Jenkins, M.K., Chen, C.A., Jung, G., Mueller, D.L., and Schwartz, R.H. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144:16-22.
9. Rathmell, J.C., and Thompson, C.B. 2002. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell. 109(Suppl):S97-S107.
10. Wells, A.D., et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303-1307.
11. Turka, L.A., et al. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. U. S. A. 89:11102-11105.
12. Frauwirth, K.A., and Thompson, C.B. 2002. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109:295-299. doi:10.1172/JC1200214941.
13. Raab, M., Pfister, S., and Rudd, C.E. 2001. CD28 signaling via VAV/SLP-76 adaptors: regulation of cyrokine transcription independent of TCR ligation. Immunity. 15:921-933.
14. Marinari, B., et al. 2002. Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur. J. Immunol. 32:447-456.
15. Khoshnan, A., et al. 2000. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J. Immunol. 165:1743-1754.
16. Burr, J.S., et al. 2001. Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-XL. J. Immunol. 166:5331-5335.
17. Okkenhaug, K., et al. 2001. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat. Immunol. 2:325-332.
18. + T lymphocytes. J. Clin. Invest. 111:1133-1145. doi:10.1172/JC1200316432.
19. Sausville, E.A., Elsayed, Y., Monga, M., and Kim, G. 2003. Signal transduction-directed cancer treatments. Annu. Rev. Pharmacol. Toxicol. 43:199-231.
20. Druker, B.J., et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-1037.